Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Who gets genomic testing for breast cancer recurrence risk?

DeFrank JT, Salz T, Reeder-Hayes K, Brewer NT.

Public Health Genomics. 2013;16(5):215-22. doi: 10.1159/000353518. Epub 2013 Jul 30.

2.

Women's experiences with genomic testing for breast cancer recurrence risk.

Tzeng JP, Mayer D, Richman AR, Lipkus I, Han PK, Valle CG, Carey LA, Brewer NT.

Cancer. 2010 Apr 15;116(8):1992-2000. doi: 10.1002/cncr.24990.

3.

Retention and use of breast cancer recurrence risk information from genomic tests: the role of health literacy.

Lillie SE, Brewer NT, O'Neill SC, Morrill EF, Dees EC, Carey LA, Rimer BK.

Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):249-55. Epub 2007 Jan 30.

4.

Knowledge of genomic testing among early-stage breast cancer patients.

Richman AR, Tzeng JP, Carey LA, Retèl VP, Brewer NT.

Psychooncology. 2011 Jan;20(1):28-35. doi: 10.1002/pon.1699.

PMID:
20200857
5.

Understanding how breast cancer patients use risk information from genomic tests.

DeFrank JT, Carey LA, Brewer NT.

J Behav Med. 2013 Dec;36(6):567-73. doi: 10.1007/s10865-012-9449-6. Epub 2012 Aug 10.

6.

Association between genomic recurrence risk and well-being among breast cancer patients.

Retèl VP, Groothuis-Oudshoorn CG, Aaronson NK, Brewer NT, Rutgers EJ, van Harten WH.

BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295.

7.

Health literacy and cancer risk perception: implications for genomic risk communication.

Brewer NT, Tzeng JP, Lillie SE, Edwards AS, Peppercorn JM, Rimer BK.

Med Decis Making. 2009 Mar-Apr;29(2):157-66. doi: 10.1177/0272989X08327111. Epub 2008 Dec 2.

PMID:
19050227
8.

Improving communication of breast cancer recurrence risk.

Brewer NT, Richman AR, DeFrank JT, Reyna VF, Carey LA.

Breast Cancer Res Treat. 2012 Jun;133(2):553-61. doi: 10.1007/s10549-011-1791-9. Epub 2011 Oct 1.

9.

Women's interest in gene expression analysis for breast cancer recurrence risk.

O'Neill SC, Brewer NT, Lillie SE, Morrill EF, Dees EC, Carey LA, Rimer BK.

J Clin Oncol. 2007 Oct 10;25(29):4628-34.

10.

Knowledge about genomic recurrence risk testing among breast cancer survivors.

Lipkus IM, Vadaparampil ST, Jacobsen PB, Miree CA.

J Cancer Educ. 2011 Dec;26(4):664-9. doi: 10.1007/s13187-011-0248-5.

PMID:
21688183
11.

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.

Hall PS, McCabe C, Stein RC, Cameron D.

J Natl Cancer Inst. 2012 Jan 4;104(1):56-66. doi: 10.1093/jnci/djr484. Epub 2011 Dec 2.

12.

When genomic and standard test results diverge: implications for breast cancer patients' preference for chemotherapy.

Brewer NT, Edwards AS, O'Neill SC, Tzeng JP, Carey LA, Rimer BK.

Breast Cancer Res Treat. 2009 Sep;117(1):25-9. doi: 10.1007/s10549-008-0175-2. Epub 2008 Sep 11.

PMID:
18785002
13.

Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer.

Chen C, Dhanda R, Tseng WY, Forsyth M, Patt DA.

J Oncol Pract. 2013 Jul;9(4):182-7. doi: 10.1200/JOP.2012.000638. Epub 2013 Feb 12.

14.

The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.

McVeigh TP, Hughes LM, Miller N, Sheehan M, Keane M, Sweeney KJ, Kerin MJ.

Eur J Cancer. 2014 Nov;50(16):2763-70. doi: 10.1016/j.ejca.2014.08.002. Epub 2014 Sep 15.

15.

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.

Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S, Lieberman N.

Breast Cancer Res Treat. 2013 Jul;140(1):83-92. doi: 10.1007/s10549-013-2603-1. Epub 2013 Jun 26.

16.

The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.

de Boer RH, Baker C, Speakman D, Chao CY, Yoshizawa C, Mann GB.

Med J Aust. 2013 Aug 5;199(3):205-8.

PMID:
23909545
17.

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI.

Am J Surg. 2008 Oct;196(4):527-9. doi: 10.1016/j.amjsurg.2008.06.021.

PMID:
18809056
18.

Individual and family characteristics associated with BRCA1/2 genetic testing in high-risk families.

Katapodi MC, Northouse LL, Milliron KJ, Liu G, Merajver SD.

Psychooncology. 2013 Jun;22(6):1336-43. doi: 10.1002/pon.3139. Epub 2012 Jul 24.

PMID:
22826208
19.

21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome.

Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O'Regan RM.

Cancer. 2012 Feb 1;118(3):788-96. doi: 10.1002/cncr.26180. Epub 2011 Jun 30.

20.

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.

Blohmer JU, Rezai M, Kümmel S, Kühn T, Warm M, Friedrichs K, Benkow A, Valentine WJ, Eiermann W.

J Med Econ. 2013;16(1):30-40. doi: 10.3111/13696998.2012.722572. Epub 2012 Sep 11.

PMID:
22966753
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk